Natzon (Buprenorphine)

Buprenorphine acts on opioid pathways to provide analgesia and to mitigate withdrawal symptoms.

• Chronic pain: provides analgesic relief for moderate to severe persistent pain.
• Opioid dependence: helps maintain opioid abstinence by reducing cravings and withdrawal severity.
• Opioid withdrawal: alleviates acute withdrawal signs during detoxification.

• Buprenorphine binds with high affinity to the µ‑opioid receptor as a partial agonist, producing limited analgesic activation while limiting respiratory depression. Simultaneously it antagonizes the κ‑opioid receptor, which contributes to its ability to lessen dysphoria and reduce withdrawal intensity. This dual activity underlies both its pain‑relieving and opioid‑dependence‑treatment effects.

Buprenorphine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Constipation: reduced bowel motility.
• Drowsiness: increased sleepiness or fatigue.
• Dry mouth: reduced salivation.
• Headache: transient cranial discomfort.
• Sweating: excessive perspiration.

Serious or Rare Side Effects

• Respiratory depression: slowed breathing, especially with concomitant depressants.
• Severe hypotension: marked drop in blood pressure.
• Allergic reactions: rash, itching, or anaphylaxis.
• QT prolongation: potential cardiac rhythm disturbances.

Before initiating buprenorphine therapy, clinicians should consider several safety measures.

• Assess respiratory function: evaluate baseline breathing and monitor for depression.
• Review hepatic status: adjust use in patients with severe liver impairment.
• Evaluate concomitant CNS depressants: avoid or closely monitor combined use.
• Counsel on dependence potential: discuss risks of misuse and diversion.
• Educate about driving: advise caution until individual response is known.
• Store at ambient temperature: keep in original container, protect from moisture and heat.

Buprenorphine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Benzodiazepines: combined use may cause profound respiratory depression.
• CNS depressants (e.g., barbiturates, alcohol): increase risk of sedation and respiratory compromise.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise buprenorphine plasma levels.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effect.

• MAO inhibitors: can enhance opioid effects, requiring careful observation.
• Antidepressants (e.g., SSRIs, SNRIs): may increase risk of serotonin syndrome when combined with serotonergic agents.